You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

162 Results
Document
Feb 2020
Document
Jun 2020
Document
Jun 2020
Document
Oct 2020
Document
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Feb 2021
Document
Feb 2021
Document
May 2021
Guidelines and Advice
Status: Current
ID: GL 2-30B
May 2021
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024

Pages